

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
0575/62097/JPW/JMLSerial No.  
09/638,648INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)Applicant  
David M. Stern, et al.Filing Date  
August 14, 2000Group  
1646 1632

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
TNT	5 8 6 4 0 1 8	4/16/96	Morser et al.	530	387.1	

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
TNT	WO 9 7 3 9 1 2 5	10/23/97	PCT	—	—		
TNT	WO 9 7 3 9 1 2 1	10/23/97	PCT	—	—		
TNT	WO 9 7 2 6 9 1 3	7/31/97	PCT	—	—		

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

TNT	Stern, D., AM Schmidt and Jun Wu - A Method For Treating Symptoms Of Diabetes In A Subject (PCT/US97/21197, filed November 12, 1997) (Attny Dkt. 50159-PCT)
TNT	Stern, D., Shi Du Yan, Ann Marie Schmidt - PCT International Application No. PCT/US98/21346; filed 09 OCT 98; Ligand Binding Site of RAGE, (Attny Dkt. 53447-PCT)
TNT	Stern, D., Yan, S-D. and Schmidt, A. M., U.S. Serial No. 09/374,213, filed August 13, 1999, A Method of Preventing Amyloid Disturbance of Cellular Properties and for Clearing Amyloid from Tissue (Attny. Dkt. 59472)

EXAMINER


Jhuan N. Jen

DATE CONSIDERED

4.08.02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
0575/62097/JPW/JMLSerial No.  
09/638,648INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)Applicant  
David M. Stern, et al.Filing Date  
August 14, 2000Group  
1646 1632

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

TNT	Gheresi-Egea JF, Gorevic PD, Ghiso J, Frangione BF, Patlak CS, Fenstermacher JD. Fate of cerebrospinal fluid-borne amyloid $\beta$ -peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries J Neurochem 1996;67:880-83.
TNT	Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999;97:889-901.
TNT	Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan AM, Chang LK, Sun Y, Paul SM. In Vivo expression of apolipoprotein E reduces amyloid- $\beta$ deposition in a mouse model of Alzheimer's Disease. J Clin Invest 1999; 103:R15-21.
TNT	Mackic JB, Weiss MH, Miao W, Ghiso J, Calero M, Bading J, Frangione B, Zlokovic BV. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid- $\beta$ peptide in aged squirrel monkey with cerebral amyloid angiopathy. J Neurochem 1998;70:210-5.
TNT	Mackic JB, Stins M, McComb JG, Calero M, Ghiso J, Kim KS, Yan SD, Stern D, Schmidt AM, Frangione B, Zlokovic BV. Human blood-brain barrier receptors for Alzheimer's amyloid- $\beta$ <sub>1-40</sub> : asymmetrical binding, endocytosis and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J Clin Invest 1998;102:734-743.
TNT	Neeper, M., et al. (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267: 14998-15004.

EXAMINER


Sharon N. For

DATE CONSIDERED

4.08.02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
0575/62097/JPW/JMLSerial No.  
09/638,648

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant  
David M. Stern, et al.Filing Date  
August 14, 2000Group  
1646 1632

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

TNT	Poduslo JF, Curran GL, Haggard JJ, Biere AL, Selkoe DJ. Permeability and residual plasma volume of human, Dutch variant, and rat amyloid $\beta$ -protein 1-40 at the blood-brain barrier. Neurobiol Dis 1997;4(1):27-34.
TNT	Schmidt, A-M, et al. (1992) "Isolation and characterization of binding proteins for advanced glycation endproducts from lung tissue which are present on the endothelial cell surface" J. Biol. Chem., 267:14987-14997.
TNT	Schmidt AM, Hasu M, Popov D, Zhang JH, Chen J, Yan SD, Brett J, Cao R, Kuwabara K, Gostache G, Simionescu N, Simionescu M, Stern D. Receptor for advanced glycation end products (AGE) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci USA 1994;91:8807-11.
TNT	Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM. RAGE and amyloid- $\beta$ peptide neurotoxicity in Alzheimer's disease. Nature 1996;382:685-91.
TNT	Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, Yu J, Soto C, Schmidt AM, Stern D, Kindy M. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000;6:643-51.
TNT	Zlokovic BV, et al. Clearance of amyloid- $\beta$ -peptide from brain: transport or metabolism? Nature Med. 6(7), 718-719
TNT	Zlokovic BV. Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier. Pharm Res 1995; 12(10): 1395-1406.

EXAMINER

Shane H. 2

DATE CONSIDERED

4.08.02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.